OBJECTIVE: To investigate the clinical features of Han Chinese patients with anti-neurofascin-155 (NF155) antibody-positive neuropathy. METHODS: We screened 194 patients with peripheral neuropathy for NF155 antibodies using a cell-based assay (CBA) and teased-fiber immunofluorescence assay. We summarized the clinical findings of seropositive patients. RESULTS: The sera from 17 patients reacted to human embryonic kidney 293 cells transfected with NF155. Eleven of these patients had the immunoglobulin G (IgG) 4 isotype, a younger onset age, tremor, higher levels of cerebrospinal fluid protein, a larger diameter of the lumbosacral nerve root on magnetic resonance imaging, and the distal demyelinating symmetric phenotype. Most patients responded to steroids and rituximab. For the remaining six seropositive patients in CBA, the predominant antibody isotype was IgG3, IgG1, or undetectable, and only one patient with IgG3 showed a positive result in the teased-fiber immunofluorescence assay. These patients did not share the typical features displayed by patients with the IgG4 isotype. INTERPRETATION: In the Han Chinese population, a significant proportion of patients who fulfilled the criteria for chronic inflammatory demyelinating polyradiculoneuropathy diagnosis had anti-NF155 IgG4 antibody-positive neuropathy and displayed specific phenotypes. Ambiguous staining patterns may appear, and the potential for false positivity should be considered. For patients who presented with specific phenotypes, identifying antibodies and subtypes involved a significant laboratory workup.
Clinical and diagnostic features of anti-neurofascin-155 antibody-positive neuropathy in Han Chinese.
汉族人群中抗神经纤维蛋白-155抗体阳性神经病的临床和诊断特征
阅读:5
作者:Wang Wenqing, Liu Chang, Li Wei, Zhang Dong, Shan Yi, Zheng Jinfan, Shan Jingli, Zhao Yuying, Yan Chuanzhu, Wang Qinzhou
| 期刊: | Annals of Clinical and Translational Neurology | 影响因子: | 3.900 |
| 时间: | 2022 | 起止号: | 2022 May;9(5):695-706 |
| doi: | 10.1002/acn3.51550 | 研究方向: | 神经科学 |
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
